Modification of red blood cells for laboratory quality control use

Current Opinion in Hematology

Volumn 16, Issue 6, 2009, Pages 467-472

  Henry, Stephen M ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

ABO; Cell surface engineering; Kodecytes; Quality controls

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; EPITOPE; GLYCOSIDASE; GLYCOSYLTRANSFERASE; MACROGOL;

ANTIGEN EXPRESSION; BLOOD GROUP ABO SYSTEM; ERYTHROCYTE; GOOD LABORATORY PRACTICE; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; FLOW CYTOMETRY;

ERYTHROCYTES; FLOW CYTOMETRY; HUMANS; QUALITY CONTROL;

EID: 73949149662     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328331257e     Document Type: Review

References (21)

1. James V editor. Guidelines for the Blood Transfusion Services in the UK, 7th ed. London, TSO, 2005: 1-339.
2. Francesco D. The New European Directive on in vitro diagnostics. Clin Chem Lab Med 2003; 41:1289-1298. (Pubitemid 37266116)
3. Daniels G. Human blood groups. 2nd ed. Science Oxford, Blackwell; 2002.
4. Chester M, Olsson M. The ABO blood group gene: a locus of considerable genetic diversity. Transfus Med Rev 2001; 15:177-200. (Pubitemid 32703017)
5. Heler HE, Namork E, Calkovska Z, et al. Expression of A antigens on erythrocytes of weak blood group A subgroups. Vox Sang 1994; 66:231-236.
6. Svensson L, Rydberg L, Hellberg Å, et al. Novel glycolipid variations revealed by monoclonal antibody immunochemical analysis of weak ABO subgroups of A. Vox Sang 2005; 89:27-38.
7. Storry JR. A review: modification of the red blood cell membrane and its application in blood group serology. Immunohematology 2000; 16:101-104.
8. Gilliver LG, Henry SM. Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents. International patent application no. PCT/NZ2004/000030 (publ. no. WO 2004/072306); 2004.
9. Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 2008; 94:87-95.
10. Bagnls C, Chapel S, Chlaronl J, Bailly P. A genetic strategy to control expression of human blood group antigens in red blood cells generated In vitro. Transfusion 2009; 49:967-976.
11. First report of in-vitro generation of erythroid cells exhibiting a chosen blood group phenotype using blood group encoding or silencing vectors.
12. Henry SM, Gilliver LG, Weinberg CS. Enzymatic modification of cell-surface H antigen by glycosyltransferases. International patent application no. PCT/ NZ2005/000126 (publ. no. WO 2005/121322); 2005.
13. Frame T, Carroll T, Korchagina E, et al. Synthetic glycolipid modification of red blood cell membranes. Transfusion 2007; 47:876-882. (Pubitemid 46669002)
14. th Congress of the International Society of Blood Transfusion, Cape Town, South Africa. Vox Sang 2006; 91 (suppl.3):29.
15. Huit AK, Frame T, Henry S, Olsson ML Flow cytometry evaluation of red blood cells transformed with variable amounts of synthetic A and B glycolipids. International Society of Blood Transfusion Regional Congress, Macao SAR, China, 2008 (P-322). Vox Sang 2008; 95 (Suppl 1):180.
16. Henry SM. Engineering the surface of red cells with synthetic glycolipids (KODE™ CAE) to create ABO analytical sensitivity controls and xeno-modified cells. 2nd International Symposium on ABO Incompatibility in Transplantation, Göteborg, Sweden, 2005.
17. Xenotransplantation 2005; 12:356.
18. Thorpe SJ, Fox B, Heath AB, et al. International standards for minimum potency of anti-A and anti-B blood grouping reagents: evaluation of candidate preparations in an International collaborative study. Vox Sang 2006; 91:336-344. (Pubitemid 44720169)
19. Carroll T. The value of routine process controls in Improving safety in immunohaematology testing: 3 years experience. Vox Sang 2008; 95 (Suppl 1): 175.
20. Heathcote D, Flower R, Henry S, Development of novel alloantibody screening cells: the first example of the addition of peptide antigens to human red cells using KODE™ technology. International Society of Blood Transfusion Regional Congress, Macao SAR, China, 2008 (P-303). Vox Sang 2008; 95 (Suppl 1), 174.
21. Henry S, Bovin N. The development of synthetic peptidolipids, glycolipids and other lipid-linked structures to create designer red cells. AABB 2008 Annual Meeting, October 2008, Montréal, Québec, Canada. Transfusion 2008; 48: 194A.